Henry C Fung, Chair and Professor, Department of Bone Marrow Transplant and Cellular Therapy at Fox Chase Cancer Center, shared Rahul Banerjee’s, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, post on X, adding:
“Not all double-hit myeloma is the same!
Look across three very different studies:
- OPTIMUM/MUKnine, a multicenter phase II enriched for ultra-high-risk MM;
- MASTER, a smaller single-arm phase II enriched for HR disease;
- PERSEUS, a large multicenter randomized phase III trial with a predominantly standard-risk population.
GEP clearly helps further refine risk stratification. But after almost two decades, I remain doubtful that GEP alone is the future. The future is integrated genomics, ultimately WGS/WTS.
For now: add CMA/CNV/LOH + myeloma-specific NGS to conventional cytogenetics/FISH. We can already define biological risk far better than simply counting HRCAs.
Same ‘double hit.’ Different biology. Different prognosis. ”
Quoting Rahul Banerjee’s post:
“Kudos to Martin Kaiser et al!
HR myeloma is a marathon, not a sprint. With extended MUKnine course, median PFS will be over 6 years (!) in ultra-HR MM without BsAbs or CAR-T.
But evidently, GEP will need to be the way of the future. Not all ultra-HR MM is created equal…”
You can also read:
Myeloma Paper of the Day, September 11th, Suggested by Robert Orlowski
